Company: PSTV
Filing Date: 2025-04-11
Form Type: POS AM
Source: 0001193125-25-079109
Chunk: 18

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-11
Form: POS AM
Chunk 18
---
 Series B Common Stock Warrants, as well as 25,160 shares of common stock held by Dr. Lenk and 15,502 shares of common stock underlying unvested options to purchase shares of common stock held by        
 Dr. Lenk that will vest within 60 days of April 10, 2025. The Common Warrants are subject to a beneficial ownership limitation of 4.99%, which limitation restricts the selling stockholder from exercising that portion of the Common Warrants that 
 would result in the selling stockholder owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. Dr. Lenk is a director of Plus Therapeutics and his address is c/o Plus Therapeutics, Inc.,     
 2710 Reed Road, Suite 160, Houston, Texas 77051.                                                                                                                                                                                                     |

| (14) | The shares reported under “Beneficial Ownership Before this Offering” consist of the following                                                                                                                    
 securities purchased by Mr. Greg Petersen in the May 2024 PIPE Financing: (i) 12,255 shares of common stock; (ii) 12,255 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; and |

9

| (iii) 12,255 shares of common stock issuable upon the exercise of Series B Common Stock Warrants, as well as 36,666 shares of common stock held by Mr. Petersen and 15,502 shares of                                                              
 common stock underlying unvested options to purchase shares of common stock held by Mr. Petersen that will vest within 60 days of April 10, 2025. The Common Warrants are subject to a beneficial ownership limitation of 4.99%, which limitation 
 restricts the selling stockholder from exercising that portion of the Common Warrants that would result in the selling stockholder owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation.   
 Mr. Petersen is a director of Plus Therapeutics and his address is c/o Plus Therapeutics, Inc., 2710 Reed Road, Suite 160, Houston, Texas 77051.                                                                                                  |

10

PLAN OF DISTRIBUTION The selling stockholders, which as used in this prospectus includes the selling stockholders listed in the section of this prospectus entitled “ Selling Stockholders,” together with any additional selling stockholders listed in a subsequent amendment to this prospectus, and their respective donees, pledgees, assign